Glenmark Adamant FDA Monroe Site Reinspection Could Happen ‘Any Time’
Indian Firm Also Eyeing Approval of Flovent Rival In Next Three Months, Filing More Strengths
A weak second half in Glenmark’s India business during the firm’s 2025 financial year took the gloss off its earnings somewhat for the year. However, Glenmark is plotting several avenues to return to growth, in both of its core business regions: India and the US.
